Chronic Granulomatous Disease Market Research Report – Forecast to 2030

Chronic Granulomatous Disease Market Research Report: By Diagnosis (Neutrophil Function Tests, Genetic Testing, Others), by Treatment (Infection Management, Interferon-gamma, Stem Cell Transplantation), by End-User (Hospitals, Others) - Forecast Till 2030

ID: MRFR/Pharma/4986-HCR | | Region: Global | 100 Pages         

Chronic Granulomatous Disease Market

The Chronic Granulomatous Disease Market for this is expected to reach USD 1.15 Billion by the end of the forecast period growing at a CAGR of 4.30%.

Segmentation

By Diagnosis Neutrophil Function Tests Genetic Testing Others
By Treatment Infection Management Interferon-gamma Stem Cell Transplantation
By End-User Hospitals Others

Key Players

  • Pfizer
  • Inc.
  • InterMune
  • Inc.
  • Novartis AG
  • Lonza Group
  • GlaxoSmithKline Plc
  • Eli Lilly and Company
  • Janssen Pharmaceuticals
  • Merck KGaA
  • Osiris Therapeutics
  • Inc
  • JCR Pharmaceuticals Co.
  • Ltd.
  • Maxcyte Inc.
  • and Horizon Pharma Plc

Drivers

  • Increasing expenditure on healthcare sector in the developed economies
  • Increasing research and development activities
Speak to Analyst Request a Free Sample

Chronic Granulomatous Disease Market Overview
 
The Chronic Granulomatous Disease Market is projected to reach USD 1.15 Billion by 2030 at 4.30% CAGR during the forecast period 2022-2030.

Over the forecast period, the worldwide chronic granulomatous disease market is expected to develop at a stable rate. The chronic granulomatous disease is an uncommon genetic condition that is passed down through the generations. People with this illness have weaker immune systems, putting them vulnerable to chronic inflammation as well as bacterial and fungal infections. The signs of this condition appear in early childhood or infancy. The indications and symptoms of this condition are unique to each individual. Frequent bacterial and fungal infections, swollen lymph nodes, recurrent diarrhea, and abscesses involving the liver, lungs, spleen, bones, or skin are all common indications and symptoms.

 
The market is predicted to grow as the prevalence of rare diseases rises, healthcare spending in developed economies rises, and research and development efforts expand. However, the chronic granulomatous disease market may be hampered by high diagnostic costs and a lack of awareness about the condition in developing and underdeveloped nations over the projection period. Furthermore, Chronic Granulomatous Disease Market drivers include the rising frequency of cancer and cardiovascular disease, as well as Chronic Granulomatous Disease developments. The rising prevalence of rare diseases and increased research and development activities are driving market expansion.

Segmentation


The global chronic granulomatous disease market has been segmented into type, diagnosis, treatment, and end user.


The market, on the basis of type, is segmented into X-linked chronic granulomatous disease and autosomal recessive chronic granulomatous disease.


The market, by diagnosis, has been segmented into neutrophil function tests, genetic testing, prenatal testing, and others.


The market, by treatment, has been segmented into infection management, interferon-gamma, stem cell transplantation, and others. The infection management segment has been further segmented into trimethoprim, sulfamethoxazole, itraconazole, and others.


On the basis of end user, the market has been segmented into hospitals, clinical laboratories, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic granulomatous disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European chronic granulomatous disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The chronic granulomatous disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. This market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc are some prominent player in the market.


Regional Market Summary


Global Chronic Granulomatous Disease Market Share (%), by Region, 2017


Chronic Granulomatous Disease Market Share


Source: Centers for Disease Control and Prevention (CDC), Eurostat, National Center for Biotechnology Information (NCBI)


Geographically, the Americas is anticipated to dominate the global chronic granulomatous disease market owing to a well-developed healthcare sector, rising prevalence of rare diseases, steady growing occurrence of chronic granulomatous disease (CGD), and relatively large number of research and development activities. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD in the US is around 1 in 200,000 to 1 in 250,000 births.


Europe is expected to hold the second largest position in the chronic granulomatous disease market. The market growth in this region is attributed to the rising prevalence of rare diseases and increasing research and development activities. According to the Eurostat, the gross domestic expenditure (GERD) on R&D was EUR 303 billion in the year 2016.


The chronic granulomatous disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of rare diseases, growing awareness about rare diseases, and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector, and growing prevalence of CGD and growing government initiatives for the healthcare sector. As per to an article published in the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD is 1 in 70,000 in the Israeli Arab population.


Global Chronic Granulomatous Disease Market, by Type



  • X-Linked Chronic Granulomatous Disease

  • Autosomal Recessive Chronic Granulomatous Disease


Global Chronic Granulomatous Disease Market, by Diagnosis



  • Neutrophil Function Tests

  • Genetic Testing



  • Prenatal Testing

  • Others


Global Chronic Granulomatous Disease Market, by Treatment



  • Infection Management

  • Trimethoprim

  • Sulfamethoxazole

  • Itraconazole

  • Others

  • Interferon-gamma

  • Stem cell transplantation

  • Others


Global Chronic Granulomatous Disease Market, by End-User



  • Hospitals

  • Clinical Laboratory

  • Others


Global Chronic Granulomatous Disease Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa




Recent Development


Abbott Laboratories said in February 2022 that it has created Lingo, a consumer bio wearable that can track important body signals to help people better understand their overall health and take steps to improve it. It may allow biohackers to use a continuous stream of data instead of finger-prick tests, urine samples, and breath readings.
 
OncoDNA, a genomic and prognostic firm, released the OncoDEEP kit in February 2022. The package includes a complete workflow solution that allows laboratories with Chronic Granulomatous Disease to do thorough Chronic Granulomatous Disease testing, perform robust data analysis, and assist oncologists in providing the most effective and customized treatments for their cancer patients.

Intended Audience



  • Pharmaceutical & Biopharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 1.15 Billion
  CAGR   4.30%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc
  Key Market Opportunities   Growing awareness about rare diseases, and increasing government funding for the healthcare sector
  Key Market Drivers

  • Growing prevalence of rare diseases
  • Increasing expenditure on healthcare sector in the developed economies
  • Increasing research and development activities


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Chronic granulomatous disease market would be driven by increased expenditure for infrastructural setup and research activities, government initiatives, and others.

    The market growth would be hindered by the high cost of genetic testing.

    The segments are sulfamethoxazole, itraconazole, trimethoprim, and others.

    The diagnosis segment would include genetic testing, prenatal testing, neutrophil function tests, and others.

    The players are InterMune, Inc., Pfizer, Inc., Lonza Group, Novartis AG, Eli Lilly and Company, GlaxoSmithKline Plc, Merck KGaA, Janssen Pharmaceuticals, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., Osiris Therapeutics, Inc, and Horizon Pharma Plc.